Home | Welcome to Contract Pharma   
Last Updated Wednesday, June 19 2013
Print RSS Feed

Breaking News

Related Searches:
Bioxel Wins Largest Paclitaxel Order

September 21, 2007
Bioxel Pharma, Inc. has won its largest paclitaxel order—valued at about $800,000—from a multinational pharmaceutical company that is currently completing Phase III trials for a paclitaxel-based product. Paclitaxel deliveries under the o…  Read More »
DSM Pharmaceutical Products

September 21, 2007
DSM Pharmaceutical Products has made several management appointments. Mr. Leendert Staal, currently business group director DSM Pharmaceutical Products, will be appointed president of DSM Nutritional Products, reporting to Stephan Tanda, member of t…  Read More »
Velcade Trial Gets Good Myeloma Results

September 20, 2007
Millennium Pharmaceuticals achieved positive interim results from an international Phase III VISTA trial in patients with newly diagnosed multiple myeloma that showed Velcade therapy, melphalan and prednisone (VMP), demonstrated a statistically signi…  Read More »
FDA Approves FluMist for Young Children

September 20, 2007
MedImmune, Inc. received approval from the FDA for the expanded use of FluMist (Influenza Virus Vaccine Live, Intranasal) in children two to five years of age. FluMist is now approved for active immunization for the prevention of influenza A and B vi…  Read More »
ImClone Expands IMC-A12 Development

September 20, 2007
ImClone Systems' anti-insulin-like growth factor-1 receptor (IGR-IR) monoclonal antibody (known as IMC-A12) has received 10 proposals for Phase I/II trials from the Cancer Therapy Evaluation Program (CTEP) of the Division of Cancer Treatment and Diag…  Read More »
Genzyme Begins Boston Facility Expansion

September 19, 2007
Genzyme Corp. broke ground on a $150 million expansion project at its Allston Landing manufacturing facility in Boston that will add space for manufacturing support functions and will create 90 jobs. Commercial production at Allston Landing, which…  Read More »
Financial Report: Catalent Pharma Solutions

September 19, 2007
Catalent Pharma Solutions 4Q Revenues: $451.3 million (+5%) 4Q Loss: $168.7 million (earnings were $27.6 million 4Q2006) FY Revenues: $1.7 billion (+6%) FY Loss: $127.3 million (earnings were $51 million FY2006) Comments: FY and 4Q revenue…  Read More »
Lilly

September 19, 2007
Robert J. Heine, M.D., Ph.D., F.R.C.P., will join Eli Lilly and Co. in January, 2008, as executive medical director for the diabetes and endocrine division responsible for development of Lilly's expanding diabetes and obesity R&D portfolio. Dr. H…  Read More »
AstraZeneca To Outsource Drug Manufacturing

September 17, 2007
AstraZeneca is planning to outsource all drug manufacturing activities within 10 years, according to a company statement. "Manufacturing for AstraZeneca is not a core activity," said David Smith, AstraZeneca's executive vice-president of op…  Read More »
Celera, Merck Enter Onco-Research Pact

September 17, 2007
Celera has entered into a research collaboration with Merck to develop biomarker and pharmacogenomic tests for cancer patients. Under the terms of the agreement, Celera will evaluate certain gene expression profiles identified by Merck with the goal…  Read More »
J&J's Levaquin Gains Additional Indications

September 17, 2007
The FDA has approved use of J&J's five-day, once-daily regimen of Levaquin 750 mg I.V. and oral, for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). The approval is based on results from a double-bl…  Read More »
Accenture, BMS Launch Pharmacovigilance Center

September 14, 2007
Accenture and Bristol-Myers Squibb have launched a joint center for pharmacovigilance in Chennai, India. The new center will be operated by more than 140 Accenture employees and will undertake the processing and coding of adverse event data and the g…  Read More »
Gene Logic, FDA Collaborate on Safety/Efficacy Data

September 14, 2007
Gene Logic, Inc. has entered into a collaboration with the FDA regarding quality control methods and metrics for understanding disparate genomic data sent as part of regulatory submissions. The collaboration is part of the FDA's Critical Path Initiat…  Read More »
Lilly's Evista Gains New Indication

September 14, 2007
Eli Lilly and Co. received approval from the FDA for its osteoporosis drug Evista for a new use to reduce the risk of invasive breast cancer in two populations: postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive…  Read More »
PPD, Inc.

September 13, 2007
Daniel G. Darazsdi has been appointed chief financial officer, PPD, Inc., effective October 1. Mr. Darazsdi joins the company after 25 years with Honeywell International, where he most recently served as vice president and chief financial officer of…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: